Dapagliflozin + Placebo Oral Tablet
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type1diabetes
Conditions
Type1diabetes
Trial Timeline
Feb 9, 2017 → Dec 19, 2017
NCT ID
NCT02987738About Dapagliflozin + Placebo Oral Tablet
Dapagliflozin + Placebo Oral Tablet is a phase 1 stage product being developed by AstraZeneca for Type1diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT02987738. Target conditions include Type1diabetes.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02987738 | Phase 1 | Completed |
Competing Products
2 competing products in Type1diabetes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UP421 | Sana Biotechnology | Phase 1 | 28 |
| XeriSol glucagon | Xeris Pharmaceuticals | Phase 1 | 28 |